Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection.

Wang H, Kjer-Nielsen L, Shi M, D'Souza C, Pediongco TJ, Cao H, Kostenko L, Lim XY, Eckle SBG, Meehan BS, Zhu T, Wang B, Zhao Z, Mak JYW, Fairlie DP, Teng MWL, Rossjohn J, Yu D, de St Groth BF, Lovrecz G, Lu L, McCluskey J, Strugnell RA, Corbett AJ, Chen Z.

Sci Immunol. 2019 Nov 15;4(41). pii: eaaw0402. doi: 10.1126/sciimmunol.aaw0402.

PMID:
31732518
2.

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ.

Cancer Discov. 2019 Nov 7. doi: 10.1158/2159-8290.CD-19-0541. [Epub ahead of print]

PMID:
31699796
3.

Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23.

Kansara M, Thomson K, Pang P, Dutour A, Mirabello L, Acher F, Pin JP, Demicco EG, Yan J, Teng MWL, Smyth MJ, Thomas DM.

Cancer Discov. 2019 Nov;9(11):1511-1519. doi: 10.1158/2159-8290.CD-19-0154. Epub 2019 Sep 16.

PMID:
31527131
4.

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Guillerey C, Nakamura K, Pichler AC, Barkauskas D, Krumeich S, Stannard K, Miles K, Harjunpää H, Yu Y, Casey M, Doban AI, Lazar M, Hartel G, Smith D, Vuckovic S, Teng MW, Bergsagel PL, Chesi M, Hill GR, Martinet L, Smyth MJ.

JCI Insight. 2019 Jun 13;5. pii: 125932. doi: 10.1172/jci.insight.125932.

5.

The role of NK cells and CD39 in the immunological control of tumor metastases.

Zhang H, Vijayan D, Li XY, Robson SC, Geetha N, Teng MWL, Smyth MJ.

Oncoimmunology. 2019 Apr 2;8(6):e1593809. doi: 10.1080/2162402X.2019.1593809. eCollection 2019.

PMID:
31069159
6.

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth MJ, Teng MWL.

Oncoimmunology. 2019 Mar 1;8(5):e1581530. doi: 10.1080/2162402X.2019.1581530. eCollection 2019.

PMID:
31069141
7.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL.

Clin Cancer Res. 2019 Oct 1;25(19):5743-5751. doi: 10.1158/1078-0432.CCR-18-2641. Epub 2019 Apr 30. Review.

PMID:
31040150
8.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.

Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.

9.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL.

Oncoimmunology. 2018 Nov 22;8(2):e1546068. doi: 10.1080/2162402X.2018.1546068. eCollection 2019.

10.

Cancer immunoediting and resistance to T cell-based immunotherapy.

O'Donnell JS, Teng MWL, Smyth MJ.

Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8. Review.

PMID:
30523282
11.

2018 Nobel Prize in physiology or medicine.

Smyth MJ, Teng MW.

Clin Transl Immunology. 2018 Oct 24;7(10):e1041. doi: 10.1002/cti2.1041. eCollection 2018. No abstract available.

12.

Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.

Ahern E, Smyth MJ, Dougall WC, Teng MWL.

Nat Rev Clin Oncol. 2018 Nov;15(11):676-693. doi: 10.1038/s41571-018-0095-y. Review.

PMID:
30232468
13.

IL-23 promotes the development of castration-resistant prostate cancer.

Yan J, Cua DJ, Teng MW.

Immunol Cell Biol. 2018 Oct;96(9):883-885. doi: 10.1111/imcb.12195. Epub 2018 Sep 8. No abstract available.

PMID:
30194885
14.

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ.

Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9.

PMID:
29986909
15.

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Yan J, Allen S, Vijayan D, Li XY, Harjunpää H, Takeda K, Liu J, Cua DJ, Smyth MJ, Teng MWL.

Cancer Immunol Res. 2018 Aug;6(8):978-987. doi: 10.1158/2326-6066.CIR-18-0011. Epub 2018 Jun 19.

16.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL.

Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018.

17.

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Ahern E, Harjunpää H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ.

Oncoimmunology. 2018 Feb 14;7(6):e1431088. doi: 10.1080/2162402X.2018.1431088. eCollection 2018.

18.

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ.

J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14.

19.

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ.

Oncoimmunology. 2018 Feb 1;7(5):e1424677. doi: 10.1080/2162402X.2018.1424677. eCollection 2018.

20.

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Gartlan KH, Varelias A, Koyama M, Robb RJ, Markey KA, Chang K, Wilkinson AN, Smith D, Ullah MA, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Teal BE, Cheong M, Teng MWL, Smyth MJ, Tey SK, MacDonald KPA, Hill GR.

Blood Adv. 2017 Jan 26;1(6):341-351. doi: 10.1182/bloodadvances.2016002980. eCollection 2017 Feb 14.

21.

De-novo and acquired resistance to immune checkpoint targeting.

Syn NL, Teng MWL, Mok TSK, Soo RA.

Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. Review.

PMID:
29208439
22.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Nov 22;17(12):765. doi: 10.1038/nrc.2017.110. No abstract available.

PMID:
29162946
23.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Review. Erratum in: Nat Rev Cancer. 2017 Nov 22;17 (12 ):765.

PMID:
29059149
24.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

25.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
26.

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Yan J, Smyth MJ, Teng MWL.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028530. doi: 10.1101/cshperspect.a028530. Review.

PMID:
28716888
27.

PD1 functions by inhibiting CD28-mediated co-stimulation.

O'Donnell JS, Smyth MJ, Teng MWL.

Clin Transl Immunology. 2017 May 5;6(5):e138. doi: 10.1038/cti.2017.15. eCollection 2017 May. No abstract available.

28.

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Vijayan D, Barkauskas DS, Stannard K, Sult E, Buonpane R, Takeda K, Teng MWL, Sachsenmeier K, Hay C, Smyth MJ.

Oncoimmunology. 2017 Apr 5;6(5):e1312044. doi: 10.1080/2162402X.2017.1312044. eCollection 2017.

29.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

30.

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

O'Donnell JS, Massi D, Teng MWL, Mandala M.

Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Review.

PMID:
28467889
31.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

32.

Resistance to PD1/PDL1 checkpoint inhibition.

O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Review.

PMID:
27951441
33.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

34.

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ.

Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. Epub 2016 Sep 12. Review.

35.

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

O'Donnell JS, Smyth MJ, Teng MW.

Genome Med. 2016 Oct 25;8(1):111.

36.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW.

Cancer Discov. 2016 Dec;6(12):1382-1399. Epub 2016 Sep 23.

37.

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ.

Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.

38.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

39.

Checkpoint Immunotherapy: Picking a Winner.

Teng MW, Khanna R, Smyth MJ.

Cancer Discov. 2016 Aug;6(8):818-20. doi: 10.1158/2159-8290.CD-16-0694.

40.

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kühnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ.

Cancer Discov. 2016 Apr;6(4):446-59. doi: 10.1158/2159-8290.CD-15-0944. Epub 2016 Jan 19.

41.

Combination cancer immunotherapies tailored to the tumour microenvironment.

Smyth MJ, Ngiow SF, Ribas A, Teng MW.

Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. doi: 10.1038/nrclinonc.2015.209. Epub 2015 Nov 24. Review.

PMID:
26598942
42.

TIGIT predominantly regulates the immune response via regulatory T cells.

Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC.

J Clin Invest. 2015 Nov 2;125(11):4053-62. doi: 10.1172/JCI81187. Epub 2015 Sep 28.

43.

From mice to humans: developments in cancer immunoediting.

Teng MW, Galon J, Fridman WH, Smyth MJ.

J Clin Invest. 2015 Sep;125(9):3338-46. doi: 10.1172/JCI80004. Epub 2015 Aug 4. Review.

44.

Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects.

Gartlan KH, Markey KA, Varelias A, Bunting MD, Koyama M, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Cheong M, Teal BE, Lor M, Comerford I, Teng MW, Smyth MJ, McCluskey J, Rossjohn J, Stockinger B, Boyle GM, Lane SW, Clouston AD, McColl SR, MacDonald KP, Hill GR.

Blood. 2015 Sep 24;126(13):1609-20. doi: 10.1182/blood-2015-01-622662. Epub 2015 Jul 23.

PMID:
26206951
45.

Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease.

Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, Locke KR, Lineburg KE, Teal BE, Leveque-El Mouttie L, Bunting MD, Vuckovic S, Zhang P, Teng MW, Varelias A, Tey SK, Wockner LF, Engwerda CR, Smyth MJ, Belz GT, McColl SR, MacDonald KP, Hill GR.

J Exp Med. 2015 Jul 27;212(8):1303-21. doi: 10.1084/jem.20150329. Epub 2015 Jul 13.

46.

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ.

Nat Med. 2015 Jul;21(7):719-29. doi: 10.1038/nm.3895. Epub 2015 Jun 29. Review.

PMID:
26121196
47.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15. No abstract available.

48.

Classifying Cancers Based on T-cell Infiltration and PD-L1.

Teng MW, Ngiow SF, Ribas A, Smyth MJ.

Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255. Review.

49.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

50.

Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

Oncoimmunology. 2014 Dec 15;3(10):e958952. eCollection 2014 Nov.

Supplemental Content

Support Center